The New Build
We recorded this just after Allbirds made headlines this month for selling its footwear assets, but before they announced their pivot to AI infrastructure under a new name — all roughly two years after Joey Zwillinger stepped down as CEO. He founded the company in 2015, took it public at a $4 billion valuation in 2021, then watched the stock collapse more than 96% before stepping down in March 2024. Rather than retreat, he's back—building Biologica, a women's hormonal health company, with lessons that only come from living through the full lifecycle of building, losing, and starting over. In this episode, Emmanuel talks with Joey about what actually broke at Allbirds, why being a public company made the turnaround harder, and the specific frameworks he's applying differently the second time around. You'll hear his "slope of ignorance" hiring philosophy, why he believes "take the money and spend like you don't have it," and what advice he's giving early-stage founders today that's genuinely different from five years ago. Topics covered: * From biotech to footwear: Why Allbirds was always a material innovation company * The "slope of ignorance": Hiring for competitive moats, not urgency * Selling $1M in shoes in 30 days with zero advertising * What broke after the $4B IPO: False signals from COVID's volatile consumer behavior * Why the $160 Tree Flyer running shoe was a strategic mistake * The public company trap: Quarterly reporting creating negative externalities * Why being too small as a public company ($300M revenue) made turnarounds brutal * Stepping down as CEO: The transition process with Joe Vernachio * Starting Biologica with his wife Liz: Hormonal age, not chronological age * What he's doing differently: Subscription model, lean team (6 people), research-first * The second-time founder paradox: People assume you'll succeed (and stop giving honest feedback) * "Spend like you don't have it": The investor advice he didn't internalize until too late * Why the music will stop: Capital allocation in an optimistic market * Building vs. buying technology: Why consumer companies shouldn't build their own tech Find this episode’s full show notes here: * https://bubble.io/blog/the-new-build-08-joey-zwillinger [https://bubble.io/blog/the-new-build-08-joey-zwillinger] Links: * Biologica: https://biologica.com [https://biologica.com] * Joey on LinkedIn: https://www.linkedin.com/in/jzwillinger [https://www.linkedin.com/in/jzwillinger]
11 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The New Build!